All the news Showing 10 of 81 articles from: TreatmentGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Stopping antivirals may offer a chance for a hepatitis B cure Liz Highleyman / 06 September 2020 Discontinuation of long-term nucleoside/nucleotide antiviral treatment for hepatitis B can allow some people to achieve a cure, according to a pair of presentations last week at the 2020 Digital International Liver Congress. This may happen ... Gilead immune modulator has modest effect on hepatitis B surface antigen Keith Alcorn / 01 September 2020 Selgantolimod, a toll-like receptor agonist designed to enhance immune responses to hepatitis B virus, showed only modest effects on hepatitis B surface antigen levels in a phase 2 safety and efficacy study presented ... JNJ-3989 achieves sustained reductions in hepatitis B surface antigen Keith Alcorn / 29 August 2020 Johnson & Johnson’s short interfering RNA treatment for hepatitis B resulted in sustained reductions in hepatitis B surface antigen when combined with nucleoside analogue drugs, Professor Edward Gane of Auckland City Hospital, New ... GSK antisense agent for hepatitis B shows promise Keith Alcorn / 29 August 2020 An antisense agent, GSK-3228836, significantly reduced hepatitis B surface antigen levels in previously untreated people with chronic hepatitis B after three injections, an early phase trial reported this week at the Digital International ... Hepatitis B treatment suboptimal in people with HIV in Africa Keith Alcorn / 04 February 2020 Testing for chronic hepatitis B infection was very low in people living with HIV in Cameroon, a country with a high burden of hepatitis B, and suppression of hepatitis B virus was ... Hepatitis B antiviral drugs reduce liver cancer risk Liz Highleyman / 19 November 2019 Treating hepatitis B virus (HBV) with nucleoside/nucleotide antiviral drugs was associated with a lower risk of developing hepatocellular carcinoma (HCC), the most common type of liver cancer, according to studies presented last week ... Therapeutic hepatitis B vaccine may lead to functional cure Liz Highleyman / 13 November 2019 An experimental therapeutic vaccine called NASVAC, which targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface antigen (HBsAg) levels, according to study presented this week ... FDA warns of rare cases of serious liver injury with newer hepatitis C drugs Keith Alcorn / 29 August 2019 The US Food and Drug Administration (FDA) has issued a warning about the risk of serious liver injury in people with hepatitis C after starting recently approved direct-acting antiviral regimens that contain ... Tenofovir may lower the risk of liver cancer more than entecavir Liz Highleyman / 18 April 2019 People with hepatitis B who were treated with tenofovir disoproxil fumarate (TDF; Viread) were less likely to develop hepatocellular carcinoma (HCC) than those treated with entecavir (Baraclude) in a large observational study, according ... Core protein inhibitor shows promising activity against hepatitis B Liz Highleyman / 16 April 2019 An experimental hepatitis B virus (HBV) core protein inhibitor led to greater reductions in HBV viral load and residual HBV genetic material when added to nucleoside/nucleotide analogues, which could lead to a functional ... ← Prev12345...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive